| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 418 | 3.160 | 5.914 | 10.817 |
| Total Income - EUR | - | - | - | - | - | - | 418 | 3.160 | 5.914 | 10.817 |
| Total Expenses - EUR | - | - | - | - | - | - | 226 | 200 | 1.152 | 2.768 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | 192 | 2.961 | 4.762 | 8.049 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | 180 | 2.866 | 4.000 | 6.916 |
| Employees | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Arggo Dopamine S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | - | - | 864 | 4.028 | 8.185 | 14.722 |
| Inventories | - | - | - | - | - | - | 358 | 359 | 358 | 356 |
| Receivables | - | - | - | - | - | - | 236 | 873 | 604 | 2.867 |
| Cash | - | - | - | - | - | - | 270 | 2.795 | 7.223 | 11.499 |
| Shareholders Funds | - | - | - | - | - | - | 220 | 3.087 | 7.078 | 13.954 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 644 | 941 | 1.107 | 768 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "9329 - 9329" | |||||||||
| CAEN Financial Year |
4791
|
|||||||||
Comments - Arggo Dopamine S.r.l.